| アブストラクト | BACKGROUND: The association between anti-vascular endothelial growth factor (VEGF) drugs and ocular adverse events (AEs) has been reported, but large real-world studies of their association with systemic AEs are still lacking. METHODS: A disproportionality analysis of reports from the FDA Adverse Event Reporting System from January 2004 to September 2021 was conducted to detect the significant ADR signals with anti-VEGF drugs (including aflibercept, bevacizumab, brolucizumab, pegaptanib, and ranibizumab). RESULTS: A total of 2980 reported cases with 7125 drug-AEs were included. Five drugs were all associated with eye disorders, and pegaptanib and ranibizumab were also associated with cardiac disorders. For ranibizumab, pegaptanib, bevacizumab and aflibercept, the proportions of cardiac AEs were 8.57%, 5.62%, 3.43% and 3.20%, respectively, and the proportions of central nervous AEs were 8.81%, 7.41, 5.86% and 5.68%, respectively. In multiple comparisons, ranibizumab was significantly higher than bevacizumab and aflibercept in the proportion of cardiac AEs (P < 0.001), and ranibizumab was significantly higher than aflibercept in central nervous AEs (P < 0.001). CONCLUSIONS: Our findings support the associations between anti-VEGF drugs and ocular AEs, cardiac AEs, and central nervous AEs. After intravitreal injection, attention should not only be paid to ocular symptoms, but also to systemic symptoms. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| 投稿日 | 2023/9/4 |
|---|
| 投稿者 | Zhou, Ruishan; Lu, Peiwen; He, Mingxiu; Chen, Junheng; Shi, Yiyang; Han, Fangfang; Cai, Yongming |
|---|
| 組織名 | School of Public Health, Guangdong Pharmaceutical University, Guangzhou, China.;School of Medical Information and Engineering, Guangdong Pharmaceutical;University, Guangzhou, China.;NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance,;Guangzhou, China.;Guangdong Provincial Traditional Chinese Medicine Precision Medicine Big Data;Engineering Technology Research Center, Guangzhou, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37665052/ |
|---|
